The authors present the results of treatment in 51 patients with vitreous haemorrhage in the course of diabetic retinopathy by application of a transconjunctival scleral cryoapplication. In the result of clinical observations it was concluded that this method was successful in the majority of the patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Analysis of 5-year efficacy of adjuvant external drainage of subretinal fluid therapy in Coats disease with severe exudative retinal detachment].
Zhonghua Yan Ke Za Zhi
March 2025
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China.
To study the 5-year long-term efficacy and complications of adjuvant external drainage of subretinal fluid therapy in patients with severe exudative retinal detachment (ERD) secondary to stage 3B juvenile Coats disease. This was a retrospective case series study. From January 2014 to December 2018, twenty-three eyes of 23 patients with severe ERD secondary to stage 3B juvenile Coats disease diagnosed at Beijing Tongren Hospital, Capital Medical University were included in this study.
View Article and Find Full Text PDFVasoproliferative Retinal Tumors: Manifestations, Management, and Outcomes in a Case Series.
Case Rep Ophthalmol
December 2024
Department of Ophthalmology, Unidade Local de Saúde de São João, Porto, Portugal.
Introduction: Vasoproliferative retinal tumors (VPRTs) are rare, benign retinal lesions characterized by abnormal vascular proliferation. They may appear sporadically or with systemic conditions like von Hippel-Lindau disease, often resembling other retinal lesions and posing diagnostic challenges. VPRTs can lead to vision loss if not adequately managed.
View Article and Find Full Text PDF[Retinal vasoproliferative tumor (retinal reactive astrocytic tumor)].
J Fr Ophtalmol
March 2025
Service d'ophtalmologie, hôpitaux universitaires de Strasbourg, 1, quai Louis-Pasteur, 67000 Strasbourg, France.
Retinal vasoproliferative tumor, otherwise known as retinal reactive astrocytic tumor, is a rare entity presenting as a mass in the inferior peripheral retina, associated with vascular abnormalities, and usually accompanied by exudative manifestations that affect the visual prognosis. The precise etiology is unknown, but the predominantly astrocytic and reactive nature of these lesions now appears to be established. It is classified as primary or secondary, and numerous associated ocular conditions have been reported, including pigmentary retinopathy, pars planitis and Coats' disease.
View Article and Find Full Text PDFTranscorneal Vitrectomy In Eyes With Regressed Retinoblastoma.
Retina
December 2024
Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California; and.
Purpose: Current treatments for retinoblastoma facilitate globe salvage but can result in vitreoretinal disorders that may require surgery. There is controversy on surgical approaches in eyes with retinoblastoma. Here, we describe a transcorneal vitrectomy approach that avoids the use of chemotherapy or cryotherapy.
View Article and Find Full Text PDFClinical Profiles of Retinal Vasoproliferative Tumors.
J Vitreoretin Dis
November 2024
Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.
Article Synopsis
- * The average age of patients at diagnosis was around 37 years, with most tumors being secondary rather than primary, and they were primarily located in the inferior and inferotemporal quadrants of the retina.
- * Treatment options such as cryotherapy and laser photocoagulation led to tumor regression in 18 out of the 19 eyes after a follow-up period of about 25 months, indicating these methods are generally effective but may require multiple sessions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!